Matches in SemOpenAlex for { <https://semopenalex.org/work/W3172972885> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W3172972885 endingPage "S52" @default.
- W3172972885 startingPage "S52" @default.
- W3172972885 abstract "Development of innovative new oncology agents with premium pricing presents challenges to payers as they seek to balance clinical need with cost-effectiveness. An analysis was performed on health technology assessments (HTA) in 2020, conducted by NICE (England and Wales), SMC (Scotland), PBAC (Australia), and CADTH (Canada). Oncology treatments approved by the European Medicines Agency and assessed by NICE, SMC, PBAC, and CADTH were reviewed, and the HTA decisions analysed. The analysis was conducted using an in-house oncology HTA database describing the key clinical and economic data used to support over 1,200 HTA decisions. In 2020, NICE published guidance for 27 oncology treatments, of which 93% were recommended, an increase from 92% in 2019 and 86% in 2018. The majority of treatments with positive recommendations (19 of 25) were recommended with a commercial arrangement, while six were recommended through the Cancer Drugs Fund (CDF), a smaller proportion than those recommended through the CDF in 2019. SMC published guidance for 24 oncology treatments in 2020; all were recommended, of which 37.5% were restricted recommendations. CADTH conditionally recommended 75% of 24 treatments, mostly based on cost-effectiveness being improved to an acceptable level, while a further 8% were recommended unconditionally. PBAC published 16 HTAs in 2020, of which 69% received a positive recommendation. The majority of oncology treatments received a positive recommendation in all countries. In England and Wales, inclusion of a commercial arrangement was a key factor in facilitating a positive recommendation while cost-effectiveness considerations were also a factor in Canada. PBAC issued the highest number of negative recommendations followed by CADTH. There was limited agreement on the treatments with negative recommendations with only one treatment not recommended by both PBAC and CADTH. The main driver of the negative recommendation in both assessments was uncertainty in clinical benefit." @default.
- W3172972885 created "2021-06-22" @default.
- W3172972885 creator A5002480333 @default.
- W3172972885 creator A5003638648 @default.
- W3172972885 creator A5009347579 @default.
- W3172972885 creator A5012955888 @default.
- W3172972885 creator A5026855688 @default.
- W3172972885 date "2021-06-01" @default.
- W3172972885 modified "2023-10-15" @default.
- W3172972885 title "PCN176 A Multinational Comparison of HTA Decisions for New Treatment Options in Oncology in 2020" @default.
- W3172972885 doi "https://doi.org/10.1016/j.jval.2021.04.267" @default.
- W3172972885 hasPublicationYear "2021" @default.
- W3172972885 type Work @default.
- W3172972885 sameAs 3172972885 @default.
- W3172972885 citedByCount "0" @default.
- W3172972885 crossrefType "journal-article" @default.
- W3172972885 hasAuthorship W3172972885A5002480333 @default.
- W3172972885 hasAuthorship W3172972885A5003638648 @default.
- W3172972885 hasAuthorship W3172972885A5009347579 @default.
- W3172972885 hasAuthorship W3172972885A5012955888 @default.
- W3172972885 hasAuthorship W3172972885A5026855688 @default.
- W3172972885 hasBestOaLocation W31729728851 @default.
- W3172972885 hasConcept C10138342 @default.
- W3172972885 hasConcept C126322002 @default.
- W3172972885 hasConcept C142724271 @default.
- W3172972885 hasConcept C143998085 @default.
- W3172972885 hasConcept C144133560 @default.
- W3172972885 hasConcept C158016649 @default.
- W3172972885 hasConcept C160735492 @default.
- W3172972885 hasConcept C17744445 @default.
- W3172972885 hasConcept C199360897 @default.
- W3172972885 hasConcept C199539241 @default.
- W3172972885 hasConcept C21333345 @default.
- W3172972885 hasConcept C2776125615 @default.
- W3172972885 hasConcept C2779256446 @default.
- W3172972885 hasConcept C41008148 @default.
- W3172972885 hasConcept C512399662 @default.
- W3172972885 hasConcept C71924100 @default.
- W3172972885 hasConceptScore W3172972885C10138342 @default.
- W3172972885 hasConceptScore W3172972885C126322002 @default.
- W3172972885 hasConceptScore W3172972885C142724271 @default.
- W3172972885 hasConceptScore W3172972885C143998085 @default.
- W3172972885 hasConceptScore W3172972885C144133560 @default.
- W3172972885 hasConceptScore W3172972885C158016649 @default.
- W3172972885 hasConceptScore W3172972885C160735492 @default.
- W3172972885 hasConceptScore W3172972885C17744445 @default.
- W3172972885 hasConceptScore W3172972885C199360897 @default.
- W3172972885 hasConceptScore W3172972885C199539241 @default.
- W3172972885 hasConceptScore W3172972885C21333345 @default.
- W3172972885 hasConceptScore W3172972885C2776125615 @default.
- W3172972885 hasConceptScore W3172972885C2779256446 @default.
- W3172972885 hasConceptScore W3172972885C41008148 @default.
- W3172972885 hasConceptScore W3172972885C512399662 @default.
- W3172972885 hasConceptScore W3172972885C71924100 @default.
- W3172972885 hasLocation W31729728851 @default.
- W3172972885 hasOpenAccess W3172972885 @default.
- W3172972885 hasPrimaryLocation W31729728851 @default.
- W3172972885 hasRelatedWork W1998789574 @default.
- W3172972885 hasRelatedWork W2025373866 @default.
- W3172972885 hasRelatedWork W2033454295 @default.
- W3172972885 hasRelatedWork W2075284547 @default.
- W3172972885 hasRelatedWork W2544355323 @default.
- W3172972885 hasRelatedWork W2799723674 @default.
- W3172972885 hasRelatedWork W2898166313 @default.
- W3172972885 hasRelatedWork W2995473795 @default.
- W3172972885 hasRelatedWork W2997067502 @default.
- W3172972885 hasRelatedWork W4311341636 @default.
- W3172972885 hasVolume "24" @default.
- W3172972885 isParatext "false" @default.
- W3172972885 isRetracted "false" @default.
- W3172972885 magId "3172972885" @default.
- W3172972885 workType "article" @default.